Premium
Growth hormone releasing peptide‐6 acts as a survival factor in glutamate‐induced excitotoxicity
Author(s) -
DelgadoRubín de Célix Arancha,
Chowen Julie A.,
Argente Jesús,
Frago Laura M.
Publication year - 2006
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2006.04122.x
Subject(s) - glutamate receptor , excitotoxicity , programmed cell death , medicine , hypothalamus , endocrinology , neuroprotection , biology , agonist , apoptosis , cerebellum , growth factor , caspase , microbiology and biotechnology , receptor , chemistry , biochemistry , pharmacology
Chronic systemic treatment given to adult male rats with growth hormone releasing peptide‐6, an agonist of the ghrelin receptor, increases insulin‐like growth factor I levels in various brain regions, including the hypothalamus and cerebellum. Furthermore, intracellular signalling cascades normally associated with anti‐apoptotic actions are activated in the same areas and are coincident with decreased basal cell death. Because abnormally high concentrations of glutamate can lead to overexcitation of neurones leading to cell damage and/or death, we investigated whether administration of growth hormone releasing peptide‐6 attenuates monosodium glutamate‐induced apoptosis in the rat hypothalamus and cerebellum. Glutamate increased activation of caspase 9 followed by cleavage of caspase 7, which in turn fragmented poly(ADP‐ribose) polymerase, terminating in cell death in both the hypothalamus and cerebellum. Growth hormone releasing peptide‐6 reversed glutamate‐induced cell death by decreasing activation of caspases 9 and 7 and poly(ADP‐ribose) polymerase fragmentation. These results provide a better understanding of the neuroprotective role of growth hormone secretagogues and the mechanisms involved.